LIPO-202 + Placebo

Phase 3Completed
0 views this week 0 watching💤 Quiet
Interest: 30/100
30
Hype Score

Development Stage

Pre-clinical
Phase 1
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Central Abdominal Bulging

Conditions

Central Abdominal Bulging

Trial Timeline

Apr 9, 2015 → Oct 29, 2015

About LIPO-202 + Placebo

LIPO-202 + Placebo is a phase 3 stage product being developed by Evofem Biosciences for Central Abdominal Bulging. The current trial status is completed. This product is registered under clinical trial identifier NCT02398188. Target conditions include Central Abdominal Bulging.

What happened to similar drugs?

4 of 19 similar drugs in Central Abdominal Bulging were approved

Approved (4) Terminated (2) Active (13)
amphotericin B liposomal (Ambisome)Astellas PharmaApproved
Pregabalin + PlaceboPfizerApproved
Aflibercept (2.0 mg)Regeneron PharmaceuticalsApproved
🔄Placebo + MirogabalinDaiichi SankyoPhase 3
🔄Tirabrutinib + Rituximab + TemozolomideOno PharmaceuticalPhase 3
🔄Leuprolide Acetate (LA)AbbViePhase 3

Hype Score Breakdown

Clinical
17
Activity
8
Company
5
Novelty
0
Community
0

Clinical Trials (2)

NCT IDPhaseStatus
NCT02483533Phase 3Terminated
NCT02398188Phase 3Completed

Competing Products

20 competing products in Central Abdominal Bulging

See all competitors
ProductCompanyStageHype Score
Placebo + MirogabalinDaiichi SankyoPhase 3
40
filgrastim + exatecan mesylateDaiichi SankyoPhase 1
29
amphotericin B liposomal (Ambisome)Astellas PharmaApproved
43
Methotrexate + Ibrutinib + TemozolomideSun PharmaceuticalPhase 2
31
alcohol + placebo + alcohol + perampanel + perampanel + alcohol + placebo + alcoholEisaiPhase 1
29
perampanelEisaiPhase 2
35
Tirabrutinib + PlaceboOno PharmaceuticalPhase 2
42
TirabrutinibOno PharmaceuticalPhase 1
36
ONO-4059 + Rituximab + Methotrexate + Procarbazine + VincristineOno PharmaceuticalPhase 1
33
Tirabrutinib + Rituximab + TemozolomideOno PharmaceuticalPhase 3
47
Tirabrutinib + Tirabrutinib + TirabrutinibOno PharmaceuticalPhase 2
39
pemetrexedEli LillyPhase 1
29
HRS-9231 + GadobutrolJiangsu Hengrui MedicinePhase 2
42
Leuprolide Acetate (LA)AbbViePhase 3
40
AcalabrutinibAstraZenecaPhase 2
39
Durvalumab + AcalabrutinibAstraZenecaPhase 1
33
Avelumab + LenvatinibMerckPhase 1
33
temozolomideMerckPhase 3
44
Ibrutinib + Pembrolizumab + RituximabMerckPhase 1/2
39
TemozolomideMerckPhase 2
35